Showing 2131-2140 of 5909 results for "".
- European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10https://modernod.com/news/european-medicines-agency-grants-prime-access-to-proqrs-sepofarsen-for-lebers-congenital-amaurosis-10/2476779/ProQR Therapeutics announced that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 gene for the treatment of Leber’s congenital amaurosis 10 (LCA10), was granted access to the Priority Medicines (PRIME) program by the European Med
- Clerio Vision Acquires Manufacturer of Extreme H2O Contact Lenseshttps://modernod.com/news/clerio-vision-acquires-manufacturer-of-extreme-h2o-contact-lenses/2476732/Clerio Vision announced that it has acquired Hydrogel Vision Corporation (HVC), a manufacturer and distributor of contact lenses. Terms of the deal were not disclosed. HVC, founded in 2002, is best known for its Extreme H2O product line and its multiple differentiated offerings that
- Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenses Now Available In the United Stateshttps://modernod.com/news/bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses-now-available-in-the-united-states/2476671/Bausch + Lomb announced the US launch of Bausch + Lomb Ultra Multifocal for Astigmatism contact lenses. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision n
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- SightGlass Vision Presents Clinical Trial Data From Novel Lenses to Control Myopiahttps://modernod.com/news/sightglass-vision-presents-clinical-trial-data-from-novel-lenses-to-control-myopia/2476541/SightGlass Vision announced that data assessing the tolerability of three iterations of its novel lenses designed to control nearsightedness in children were presented at the Association for Research in Vision and
- IBM’s New AI Technique Could Detect Glaucoma Earlierhttps://modernod.com/news/ibms-new-ai-technique-could-detect-glaucoma-earlier/2476530/At ARVO, IBM researchers presented new techniques in deep learning that could help unlock earlier glaucoma detection. IBM and NYU’s research demonstrates how deep learning models can be trained to learn from and analyze easily-obtained retina images, and then use this analysis to directly estimat
- RadianceTx Expands Team to Develop Beta Ophthalmic Systemhttps://modernod.com/news/radiancetx-expands-team-to-develop-beta-ophthalmic-system/2476511/Radiance Therapeutics has announced the expansion of its core team. Abigail Mackrill, formerly of Ophthalmology Futures Forums and The Ophthalmologist, joins as Director of Business Development and Outreach. James Fazio, MBA, Msc Eng, formerly Global Business Leader for
- SynergEyes Launches Tangible Hydra-PEG Coating on SynergEyes VS Scleral Lenshttps://modernod.com/news/synergeyes-launches-tangible-hydra-peg-coating-on-synergeyes-vs-scleral-lens/2476394/SynergEyes announced that the SynergEyes VS scleral lens is now available with Tangible Hydra-PEG on Contamac material. The Tangible Hydra-PEG coating is designed to solve the problem of contact lens discomfort and dry eyes by minimizing deposits and lens fogging, increasing lens surface water re
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi